Not a good buy right now for an impatient entry: price is in a clear short-term downtrend and has slipped below the near support zone (~14.20), with next support around ~13.46.
Oversold RSI (6) near ~18 can produce a sharp bounce, but MACD is still deteriorating, so timing is unfavorable without a reversal trigger.
Options positioning and analysts are broadly bullish, but the tape/technicals suggest better odds after confirmation (reclaiming ~14.20–15.40) rather than buying the breakdown.
No Intellectia buy signals today to override the bearish technical setup.
Momentum: MACD histogram -0.24 and expanding negatively = selling pressure still building.
RSI: RSI_6 ~18.4 (oversold) suggests bounce potential, but oversold can persist in strong downtrends.
Levels: Pivot ~15.40 (key reclaim level). S1 ~14.20 has been breached (current ~14.06), making S2 ~13.46 the next downside magnet. Upside resistance: ~16.61 then ~17.35.
Pattern-based stats: Similar-pattern model implies +0.89% next day / +1.74% next week, but -3.2% next month (near-term bounce risk, medium-term drift lower).
Lake Street: Buy; PT raised to $23 (from $22), noting confidence the business is "back on track" after two weaker quarters.
Wall Street pros: SaaS/recurring revenue mix, competitive position (Corellium), multi-year growth levers.
Wall Street cons: recent profitability/EPS pressure and the stock’s current technical downtrend.
Influential/political trading: No recent congress trading data available; hedge funds/insiders flagged as Neutral with no notable recent trend.
Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 24.2 USD with a low forecast of 23 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 24.2 USD with a low forecast of 23 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
1 Sell
Moderate Buy
Current: 13.590
Low
23
Averages
24.2
High
25
Current: 13.590
Low
23
Averages
24.2
High
25
JPMorgan
Brian Essex
Overweight
maintain
$23 -> $24
AI Analysis
2025-11-13
Reason
JPMorgan
Brian Essex
Price Target
$23 -> $24
AI Analysis
2025-11-13
maintain
Overweight
Reason
JPMorgan analyst Brian Essex raised the firm's price target on Cellebrite to $24 from $23 and keeps an Overweight rating on the shares. The company reported solid Q3 results with "multiple levers" to drive growth in 2026, the analyst tells investors in a research note.
BofA
Buy
maintain
$24 -> $25
2025-11-13
Reason
BofA
Price Target
$24 -> $25
2025-11-13
maintain
Buy
Reason
BofA raised the firm's price target on Cellebrite to $25 from $24 and keeps a Buy rating on the shares. The firm fine tunes its estimates to reflect positive underlying trends following the company's Q3 report.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLBT
